• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bob Langer on drug delivery

February 2, 2017 By Sarah Faulkner

Bob Langer on drug delivery
Photo credit: Chemical Heritage Foundation

Robert Langer, a pioneer in drug delivery and the most cited engineer in history, has co-founded 30 companies and treated more than 20 million patients as a result of his innovations. In a conversation with Wired, he spoke about his career, which has spanned for 4 decades and began with his 1976 discovery of a method to delay delivery of large molecules.

Many new drugs are large molecules, Langer said, because they are complex and contain a lot of information. The structure of these large molelecules, including peptides, proteins and anitbodies, fall apart rapidly in the body. Langer knew that polymers could delay a drug’s release over a long period of  time, so his team carved channels into the polymer to make the technique work for molecules of any size or charge.

“
To take 1 example, the peptide hormones that people want to use to treat cancer and endometriosis are too large to be absorbed orally – and if you inject them, they’re destroyed right away. When put in the polymer systems, they can be continuously delivered 
over weeks, months or years,” he explained.

Langer has devoted his career to to engineering smarter drug delivery systems, in the hopes of improving medication adherence, he said in the interview. “In terms of compliance, sadly, fewer than 50% of people take their drugs as prescribed, which is a problem in people with Alzheimer’s, schizophrenia and other mental health diseases. This leads to more than 
$100 billion (£82bn) in costs. The New England Medical Journal showed that with hypertension in the US alone, around 100,000 deaths could’ve been prevented if people had taken their meds correctly.”

One of the systems that his team at the Massachusetts Institute of Technology is working on is a long-acting oral pill that could release an accurate drug dose for weeks. “When the capsule dissolves in the stomach, the material opens up to fix it in place until it degrades. And we can tune the degradation so this takes place on the set timescale,” he said.

Medication compliance is problem in developing countries, Langer said, so his team is collaborating with the Bill & Melinda Gates Foundation to develop an long-acting oral capsule for drugs like antimalarials.

One of his companies, Lyndra, is examining a way to treat Alzheimer’s with a pill that a patient would take once a month, instead of 4 times a day.

He also spoke about the importance of collaboration and diversity in research, saying that “it’s been very important. Different people bring different perspectives and expertise. They also bring different ideas.”

Tarveda Therapeutics, a company that Langer co-founded, said today that it secured a $30 million  Series D equity financing round led by Versant Ventures.

The company’s CEO, Drew Fromkin, told the Boston Business Journal that the investment would enable Tarveda to advance its platform of miniature antibody-drug conjugates, used to penetrate into solid tumors and deliver a drug payload.

Tarveda’s lead drug targets neuroendocrine and small cell lung cancers and is in phase I trials. The company anticipates that data will be ready by the end of this year.

Filed Under: Featured, Research & Development Tagged With: Massachusetts Institute of Technology

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS